Endpoints News 生物医药· ENDPOINTS·· 15 天前AI 评分26
Rezera 销售增长推动 RevMed 股价上涨
Rasonque sales drive RevMed's stock; whistleblower sues Madrigal over MASH
AI 导读
Rezera 是一款 RAS 药物,RevMed 公司报告其早期销售取得增长,导致公司股价上涨。
正文
Plus news about Rezera, ANI Pharmaceuticals, Cloudbreak Pharma and Anaheim Bio.
RevMed’s stock jumps on early Rasonque sales: The RAS drug developer reported sales of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news